ArticleAdvanced science (Weinheim, Baden-Wurttemberg, Germany)2026
HSP90AB1-Mediated Ubiquitin-Proteasome Degradation of ITGBL1 Promotes Osteosarcoma Progression by Inhibiting Endoplasmic Reticulum Stress-Induced Autophagy.
Article in Advanced science (Weinheim, Baden-Wurttemberg, Germany), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
18 authors.
Funding
Abstract
Osteosarcoma (OS) is one of the most malignant bone tumors in children and adolescents, but the molecular mechanisms of OS progression remain largely undefined. In this study, we demonstrate that Integrin subunit beta-like 1 (ITGBL1) is downregulated in OS tissues, and its downregulation correlates with poor prognosis in OS patients. Functional assays revealed that ITGBL1 inhibits OS cell growth, metastasis, and stemness, while promoting apoptosis. The in vitro and in vivo experiments further revealed that ITGBL1 activates endoplasmic reticulum (ER) stress by upregulating ROS, thereby triggering autophagy in OS cells. In addition, the downregulation of ITGBL1 in OS is partly attributed to the abnormal upregulation of HSP90AB1 (heat shock protein 90 alpha family class B1). Mechanistically, ITGBL1 interacts with HSP90AB1 which facilitates ITGBL1 degradation through K63-linked ubiquitination. Finally, through virtual screening and Co-IP, we identified ivermectin as a potent inhibitor of the HSP90AB1-ITGBL1 interaction, and treatment with ivermectin dramatically inhibited OS progression in vivo. In conclusion, we uncover a novel mechanism that promotes OS progression and identify a new candidate drug for the treatment of OS.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.